Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Announced record quarterly revenues driven by Epidiolex and Xywav, FDA approvals of two drugs, and positive Phase 3 trials for cancer treatment Ziihera.
— Bernard Horn
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Jazz Pharmaceuticals plc
No other institutional pitches found for this ticker yet.
More institutional theses from Polaris International Equity
Samsung Electronics fell amid geopolitical concerns regarding U.S. chip restrictions and South Korean martial law fallout. The manager views...
SK Hynix experienced short-term share price pressure due to geopolitical friction, U.S. tariff fears, and domestic South Korean political instability. However, the manager...